QC
STOK icon

Quadrature Capital’s Stoke Therapeutics STOK Stock Holding History

Quadrature Capital’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
41,225
+30,932
+301% +$993K 0.01% 637
2026
Q1 		$335K Buy
+10,293
New +$338K ﹤0.01% 928

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Quadrature Capital's STOK Position: Q2 2026 in Review

Quadrature Capital increased its Stoke Therapeutics (STOK) stake by 301% in Q2 2026, buying an estimated $993K and bringing the position to 41,225 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #637.

Quadrature Capital first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Quadrature Capital held 41,225 shares of Stoke Therapeutics worth $1.35M as of Q2 2026.
  • Quadrature Capital bought 30,932 Stoke Therapeutics shares in Q2 2026, an estimated $993K.
  • Stoke Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #637 holding.
  • Quadrature Capital first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.